• FDA allows for expanded marketing of 23andMe to include medication metabolism

    5 monthes ago - By Healio

    The FDA expanded the approved marketing of the 23andMe Personal Genome Service Pharmacogenetic Reports test to include information about 33 genetic variants that may be linked with a patient's ability to metabolize some medications to help inform discussions with a health care provider, according to an agency press release.
    “This test is a step forward in making information about genetic variants available directly to consumers and better inform their discussions with their health care providers. We know that consumers are increasingly interested in genetic information to help make
    Read more ...


  • Novel technique of filler injection in the temple area using the vein detection device

    5 monthes ago - By Journal of Plastic, Reconstructive & Aesthetic Surgery

    The increasing popularity of soft tissue fillers will inevitably result in increasing incidence of vascular injury. The temple area consists of several layers such as the superficial subcutaneous layer, superficial temporal fascia, loose areolar tissue, deep temporal fascia, temporalis muscle, and temporal bone from the zygomatic arch to the superior temporal septum. Fillers can be injected into various layers: first, the superficial subcutaneous layer; second, between the superficial temporal fascia and deep temporal fascia; and third, above the periosteum of the temporal bone.
    Read more ...


  • Certain test strips used with home-use devices may provide inaccurate results, warns FDA

    5 monthes ago - By News Medical

    The U.S. Food and Drug Administration today is warning patients and doctors, who use at-home or in-the-office medical devices to monitor levels of the blood thinner, warfarin, that certain test strips used with the devices may provide inaccurate results and should not be relied upon to adjust the drug dosage.
    Read more ...